Aurinia Pharmaceuticals is an Exciting Investment in the Biotech Space

Photo of author
Written By Joel Gbolade

Company Overview

Credits: DepositPhotos

Aurinia Pharmaceuticals, headquartered in Edmonton, Alberta, specializes in late-clinical stage biopharmaceuticals dedicated to treating kidney diseases. Its primary asset is Lupkynis (voclosporin), the first FDA-approved oral therapy for lupus nephritis (LN), approved in January 2021.

Aurinia emerged as a division of Vifor Pharma in 2012, following the merger with Isotechnika Pharma, which discovered voclosporin in the mid-1990s. Listed on the Nasdaq since 2014, Aurinia currently trades at approximately $5.50 per share, translating to a market capitalization of around $775 million.

Marking Culmination of Development Journey

Lupkynis marks the culmination of a lengthy development journey, initially explored for various conditions such as renal allograft rejection, uveitis, psoriasis, and dry eye syndrome.

The FDA’s approval for lupus nephritis addressed a critical medical need, given the severe renal damage associated with systemic lupus erythematosus (SLE). LN can lead to kidney failure within 15 years for 10%-30% of patients, underscoring the urgency of effective treatments.

Lupkynis, an optimized form of cyclosporin, operates by inhibiting calcineurin, thereby reducing cytokine activation and immune responses.

Competitive Landscape and Commercial Results

Despite being the first oral therapy approved for LN, Lupkynis faces competition from GlaxoSmithKline’s (GSK) Benlysta, approved for SLE and expanded to LN shortly before Lupkynis’ launch.

While Lupkynis boasts superior efficacy and convenience compared to Benlysta, GSK’s established market presence and broader marketing efforts have posed challenges to Aurinia’s market penetration. Initial sales figures have been modest, with FY21 sales at $45.5 million, increasing to $158.5 million in FY23.

Aurinia estimates a sizable U.S. market of approximately 100,000 LN patients but has captured only a small fraction with roughly 2,178 patients on Lupkynis as of March 2024.

Restructuring and Financial Outlook

In response to market challenges, Aurinia undertook a strategic restructuring in February 2024, focusing exclusively on enhancing Lupkynis’ market performance. This initiative included halting other development programs and reducing workforce costs by 25%, aimed at achieving annual savings of $50 million to $55 million.

As of May 2024, Aurinia reported positive financial signals, including a non-GAAP loss of $0.03 per share in 1Q24 on total net revenue of $50.3 million, marking a 46% year-over-year revenue increase.

Otsuka Collaboration and Future Prospects

Aurinia’s collaboration with Otsuka Pharmaceuticals for commercial rights in the EU, UK, and Japan provides additional revenue streams and market expansion opportunities.

Further milestones include anticipated approval of Lupkynis in Japan in 2H24, bolstering revenue with royalties and milestone payments. Additionally, Aurinia’s strong cash position, with $320.1 million in cash and investments and no debt as of March 31, 2024, supports its strategic initiatives, including a $150 million share repurchase plan aimed at enhancing shareholder value.

Analyst and Investor Perspective

Credits: DepositPhotos


Despite the challenges, Aurinia Pharmaceuticals remains resilient, with analysts projecting a positive outlook. The company’s stock, trading at an attractive forward PE ratio and price-to-sales ratio, presents potential value for investors. Analysts maintain optimistic price targets, reflecting confidence in Aurinia’s ability to navigate market dynamics and capitalize on Lupkynis’ therapeutic potential.

With a focused strategy on Lupkynis, strategic financial maneuvers, and promising partnerships, Aurinia Pharmaceuticals appears undervalued relative to its growth prospects and market position.

Investors seeking exposure to biopharmaceuticals, particularly in renal disease treatment, may find Aurinia Pharmaceuticals a compelling investment opportunity.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.